Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Abbott Laboratories    ABT

ABBOTT LABORATORIES

(ABT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Abbott Laboratories : annual earnings release

share with twitter share with LinkedIn share with facebook
share via e-mail
01/17/2020 | 09:15am EST

The company will report its earnings for FY 2019 on 01/22/2020. Generally, the company reports earnings worse than estimates. In recent months, the 7 analysts from Standard & Poor's consensus have revised their EPS estimates downward.


© MarketScreener.com 2020
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ABBOTT LABORATORIES
02/21ABBOTT LABORATORIES : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIO..
AQ
02/21ABBOTT : Declares 385th Consecutive Quarterly Dividend
PR
02/18ABBOTT : Introduces Next-Generation Heart Rhythm Management Devices in Europe, F..
PR
02/11ABBOTT LABORATORIES : Change in Directors or Principal Officers (form 8-K)
AQ
02/05WALL STREET STOCK EXCHANGE : Tiffany is part of LVMH, Tesla gives some bad news,..
02/04ABBOTT LABORATORIES : Gets FDA Breakthrough Designation for Fully Implantable He..
DJ
02/04ABBOTT : 's In-Development Fully Implantable Heart Pump System Earns FDA's Break..
PR
02/03ABBOTT : Announces First-of-Its-Kind Trial to Assess New Therapy Option for Peop..
PR
01/31ABBOTT LABORATORIES : Tendyne device receives world's first ce mark for transcat..
AQ
01/30ABBOTT : 's Tendyne™ Device Receives World's First CE Mark for Transcathet..
PR
More news
Financials (USD)
Sales 2020 34 120 M
EBIT 2020 7 754 M
Net income 2020 4 460 M
Debt 2020 10 170 M
Yield 2020 1,60%
P/E ratio 2020 34,6x
P/E ratio 2021 28,2x
EV / Sales2020 4,82x
EV / Sales2021 4,37x
Capitalization 154 B
Chart ABBOTT LABORATORIES
Duration : Period :
Abbott Laboratories Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ABBOTT LABORATORIES
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 99,28  $
Last Close Price 87,45  $
Spread / Highest target 25,8%
Spread / Average Target 13,5%
Spread / Lowest Target -10,8%
EPS Revisions
Managers
NameTitle
Miles D. White Chairman & Chief Executive Officer
Robert B. Ford President, Chief Operating Officer & Director
Brian Bernard Yoor Chief Financial Officer & Executive VP-Finance
Roxanne Schuh Austin Independent Director
Samuel C. Scott Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ABBOTT LABORATORIES0.68%154 212
MASIMO CORPORATION12.85%9 595
NOVOCURE LIMITED4.73%8 735
PENUMBRA, INC.16.95%6 708
ASAHI INTECC CO., LTD.0.33%6 386
GETINGE0.66%4 901